17-Apr-2026
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
PRNewswire (Fri, 10-Apr 1:34 PM ET)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS
PRNewswire (Wed, 8-Apr 2:15 PM ET)
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 7-Apr 2:48 PM ET)
Globe Newswire (Tue, 7-Apr 9:50 AM ET)
Globe Newswire (Tue, 7-Apr 7:31 AM ET)
Globe Newswire (Thu, 2-Apr 8:32 AM ET)
PRNewswire (Wed, 1-Apr 4:15 PM ET)
Globe Newswire (Tue, 31-Mar 7:01 PM ET)
Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 31-Mar 11:38 AM ET)
Market Chameleon (Tue, 31-Mar 5:53 AM ET)
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
Centessa Pharmaceuticals PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol CNTA.
As of April 17, 2026, CNTA stock price climbed to $39.66 with 3,428,203 million shares trading.
CNTA has a beta of 1.01, meaning it tends to be more sensitive to market movements. CNTA has a correlation of 0.05 to the broad based SPY ETF.
CNTA has a market cap of $6.13 billion. This is considered a Mid Cap stock.
Last quarter Centessa Pharmaceuticals PLC - American Depositary Shares reported $0 in Revenue and -$.48 earnings per share. This fell short of revenue expectation by $-836,730 and missed earnings estimates by -$.02.
In the last 3 years, CNTA traded as high as $40.26 and as low as $3.96.
The top ETF exchange traded funds that CNTA belongs to (by Net Assets): IBB, SPDW, FFSM, ONEQ, BBC.
CNTA has outperformed the market in the last year with a return of +222.6%, while the SPY ETF gained +36.3%. In the last 3 month period, CNTA beat the market returning +78.6%, while SPY returned +2.9%. However, in the most recent 2 weeks CNTA has underperformed the stock market by returning -0.1%, while SPY returned +8.3%.
CNTA support price is $38.16 and resistance is $40.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNTA shares will trade within this expected range on the day.
